The antiproliferative effects of the combination of anti-VEGF agents with SSAs has been tested in a series of primarily phase 1 and 2 clinical trials in patients with advanced well-differentiated NETs, as delineated below, and has demonstrated mixed anti-tumor activity overall, with no practice-changing results elicited from these studies. The gene discussed is VEGFA; the disease is neoplasm.